Teva Said Close to Closing $40.5 Billion Allergan Deal

The transcript discusses Teva's $40.5 billion acquisition of Allergan's generic drug unit, marking it as the second largest pharmaceutical deal in recent years. The deal is funded through international bond sales and requires divestitures to gain regulatory approval. Market reactions were positive, with shares rising. Teva aims to integrate Allergan's business, focusing on becoming the top generic drug maker and achieving significant savings and sales growth. Future acquisitions are not ruled out, but the primary focus remains on integration.

What are the expected savings or synergies from the deal?

What future plans does Tether have after the deal?